Binex KRX:053030KOSDAQ
바이넥스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days9
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, Binex reported revenue of ₩37.8bn, down 15.1% year on year, and an operating loss of ₩9.2bn. Binex (바이넥스) appeared in 9 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 9 articles. The most common catalyst was clinical & approvals (6). It was most often mentioned alongside 글로벌테크놀로지, SCL Science and Genolution.
Filing signals Supply contract Swung to loss Share pledge Screener
Binex quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩37.8bn | -15.1% | −₩9.2bn margin −24.2% | −₩15.0bn |
| Q1 2026 | ₩35.3bn | -11.2% | −₩9.0bn margin −25.4% | −₩9.6bn |
| Q4 2025 derived | ₩38.8bn | +7.9% | −₩6.3bn margin −16.3% | −₩3.7bn |
| Q3 2025 | ₩45.4bn | +37.8% | ₩242m margin 0.5% | −₩976m |
| Q2 2025 | ₩44.5bn | +41.5% | ₩1.0bn margin 2.3% | ₩1.4bn |
| Q1 2025 | ₩39.8bn | +33.9% | ₩541m margin 1.4% | −₩0m |
| Q4 2024 derived | ₩36.0bn | +1.2% | −₩7.1bn margin −19.8% | −₩8.2bn |
| Q3 2024 | ₩32.9bn | +4.1% | −₩4.7bn margin −14.3% | −₩11.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Binex top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Binex news Korean headlines
-
Major바이넥스 오송공장, EMA 실사 통과…상업생산 주문 확보
1 more on this story · 1 outlets
- 바이넥스, 26일 장중 상승…오송공장 EMA 실사 통과비건뉴스 · Oct 26 12:23
-
Major바이넥스, 오송공장 글로벌 제약사 PPQ 완료·첫 유럽 EMA 실사 통과
2 more on this story · 2 outlets
- [BioS]바이넥스, 'CDMO' 오송공장 "EMA 실사 통과"이투데이 · Oct 26 14:27
- 바이넥스, 오송공장 글로벌 제약사 PPQ 완료…첫 유럽 EMA 실사 ‘원샷’ 통과파이낸셜포스트 · Oct 26 15:05